| abstract |
The present invention relates generally to a pharmacological system that modulates the activity of platelet glycoprotein GPVI to modulate the biology of platelets based on nucleic acid ligands that can interact with platelet glycoprotein GPVI and to regulate platelet action. These nucleic acid ligands also use modulators that inhibit the activity of nucleic acid ligands that neutralize their pharmacological effects, thereby restoring GPVI action such as collagen binding, platelet adhesion, collagen-induced platelet activity, and collagen-induced platelet aggregation. It can be actively reversible. The present invention also relates to compositions comprising nucleic acid ligands, ligands and modulators, methods of producing nucleic acid ligands and modulators thereof, and methods of using such agents and compositions in medical treatment and diagnostic procedures. |